A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
Status:
Recruiting
Trial end date:
2022-08-24
Target enrollment:
Participant gender:
Summary
A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study
to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of iN1011-N17 after Oral
Administration in Healthy Volunteers.